Skip to main content

Table 1 Baseline characteristics of patients

From: Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

Characteristic N = 33
Median age, years (range) 54 (35–70)
   ≤ 60, n (%) 25 (75.8)
   > 60, n (%) 8 (24.2)
Gender, n (%)
  Male 17 (51.5)
  Female 16 (48.5)
Smoking history, n (%)
  Former/current 12 (36.4)
  Never 21 (63.6)
ECOG PS, n (%)
  0 24 (72.7)
  1 9 (27.3)
Brain metastases, n (%)
  Presence 13 (39.4)
  Absence 20 (60.6)
No. of lines of prior systemic treatment, n (%)
  1 17 (51.5)
  2 9 (27.3)
   ≥ 3 7 (21.2)
  Median (range) 1 (1–5)
Prior Chemotherapy, n (%)
  Yes 24 (72.7)
  No 9 (27.3)
Prior anti-HER2 TKI therapy, n (%)
  Yes 17 (51.5)
  No 16 (48.5)
HER2 alterations, n (%)
  Exon 20 insertion mutations 28 (84.8)
  A775_G776insYVMA
Non-YVMA insertions*
20 (60.6)
8 (24.2)
  TKD missense mutations** 3 (9.1)
  Amplification 2 (6.1)
  1. *Non-YVMA insertions included P780_Y781insGSP (n = 6), G776delinsVC (n = 1), and G776_V777delinsCVC (n = 1)
  2. **TKD missense mutations included G776V (n = 1) and R811L with Q820K (n = 1) at exon 20, and G727A (n = 1) at exon 18
  3. ECOG PS Eastern Cooperative Oncology Group Performance Status, TKD tyrosine kinase domain